搜索优化
Rewards
English
搜索
Copilot
图片
视频
地图
资讯
购物
更多
航班
旅游
酒店
房地产
笔记本
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
过去 7 天
时间不限
过去 1 小时
过去 24 小时
过去 30 天
按时间排序
按相关度排序
3 天
Stifel维持Blueprint Medicines买入评级,目标价155美元
周四,Stifel重申了对Blueprint Medicines (NASDAQ:BPMC)股票的买入评级,目标价为155.00美元。该公司的评论强调了Blueprint Medicines在过敏和炎症市场的进展,特别是其主打产品Ayvakit的商业成功。
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
今日热点
Shooting suspect left note
Daylight saving time
1951 kidnap victim found
Visits US ammunition plant
Ga. suspect's mom indicted
Robinson loses key staff
California plastic bag ban
Free COVID-19 tests
Economic speech this week
San Francisco homelessness
Astronauts return to Earth
Co-founder testifies
To meet Vietnamese pres
Bulls escape MA rodeo
PM Modi visits US
Iran coal mine blast
No. 1 at box office again
SpaceX plans Mars missions
Tech ban proposed
Dolphins legend Morris dies
No govt. shutdown for now
Makes emergency landing
Donlon's homes searched
ISR raids Al Jazeera office
More troops to Middle East
CA firefighter held for arson
反馈